This is a phase 2 study to determine the efficacy of huCART19 in pediatric and young adult patients with CD19-expressing high-risk relapsed or refractory B-cell acute lymphoblastic leukemia. The targeted population is patients 1-29 years with CD19-expressing high-risk relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), including patients who previously received a B cell-directed cell therapy.
Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Clinical Studies
1 - 2 of 2
CHOP, in collaboration with the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium, is conducting a study for children and young adults between the ages of 1 and 21, with relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. This clinical trial is adding the study drug, temsirolimus, to a standard relapse ALL chemotherapy regimen of etoposide and cyclophosphamide. For more information about this study, including specific eligibility criteria, please visit clinicaltrials.gov and search for "NCT01614197" or visit the TACL website at https://tacl.chla.usc.edu/Tacl/#!/Page/3. To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@email.chop.edu.